New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07408258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONC-783 (a bispecific antibody targeting CD24 and CD3)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so it is mainly checking safety and dosing. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
Contact
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States